295 related articles for article (PubMed ID: 22981500)
1. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV
Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500
[TBL] [Abstract][Full Text] [Related]
2. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
3. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).
Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau HT; Brown MP; Hamid O; Infante JR; Millward M; Pavlick A; Chin MT; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
Clin Cancer Res; 2014 Sep; 20(17):4449-58. PubMed ID: 24958809
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
5. BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.
Broski SM; Moran EK; Glazebrook KN; Nathan MA
Clin Nucl Med; 2016 Mar; 41(3):e149-51. PubMed ID: 26447389
[TBL] [Abstract][Full Text] [Related]
6.
Eschbach RS; Kazmierczak PM; Heimer MM; Todica A; Hirner-Eppeneder H; Schneider MJ; Keinrath G; Solyanik O; Olivier J; Kunz WG; Reiser MF; Bartenstein P; Ricke J; Cyran CC
Cancer Imaging; 2018 Jan; 18(1):2. PubMed ID: 29347968
[TBL] [Abstract][Full Text] [Related]
7. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
8. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
McArthur GA; Puzanov I; Amaravadi R; Ribas A; Chapman P; Kim KB; Sosman JA; Lee RJ; Nolop K; Flaherty KT; Callahan J; Hicks RJ
J Clin Oncol; 2012 May; 30(14):1628-34. PubMed ID: 22454415
[TBL] [Abstract][Full Text] [Related]
9. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Long GV; Trefzer U; Davies MA; Kefford RF; Ascierto PA; Chapman PB; Puzanov I; Hauschild A; Robert C; Algazi A; Mortier L; Tawbi H; Wilhelm T; Zimmer L; Switzky J; Swann S; Martin AM; Guckert M; Goodman V; Streit M; Kirkwood JM; Schadendorf D
Lancet Oncol; 2012 Nov; 13(11):1087-95. PubMed ID: 23051966
[TBL] [Abstract][Full Text] [Related]
10. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
11. Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.
Azer MW; Menzies AM; Haydu LE; Kefford RF; Long GV
Cancer; 2014 Feb; 120(4):530-6. PubMed ID: 24496868
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau TH; Brown MP; Hamid O; Infante JR; Millward M; Pavlick AC; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
Lancet; 2012 May; 379(9829):1893-901. PubMed ID: 22608338
[TBL] [Abstract][Full Text] [Related]
14. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
[TBL] [Abstract][Full Text] [Related]
15. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
[TBL] [Abstract][Full Text] [Related]
16. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract][Full Text] [Related]
17. Erythema Nodosum-Like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib.
Martínez-Rodríguez I; García-Castaño A; Quirce R; Jiménez-Bonilla J; Banzo I
Clin Nucl Med; 2017 Jan; 42(1):44-46. PubMed ID: 27775948
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Hauschild A; Ascierto PA; Schadendorf D; Grob JJ; Ribas A; Kiecker F; Dutriaux C; Demidov LV; Lebbé C; Rutkowski P; Blank CU; Gutzmer R; Millward M; Kefford R; Haas T; D'Amelio A; Gasal E; Mookerjee B; Chapman PB
Eur J Cancer; 2020 Jan; 125():114-120. PubMed ID: 31864178
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.
Cavalieri S; Di Guardo L; Cimminiello C; Bono A; Tolomio E; Colombetti A; Valeri B; Di Tolla G; de Braud F; Del Vecchio M
Tumori; 2016 Oct; 102(5):501-507. PubMed ID: 27470608
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
